Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.
|Articles|October 29, 2014
Supplements and Featured Publications
- Evidence-Based Cardiology - October
Evidence-Based Cardiology - October
Advertisement
Evidence-Based Cardiology is a publication designed bridge the clinical and managed care realms for those who provide care to patients and those who manage populations affected by cardiovascular conditions. In this issue, we present content relevant to practicing cardiologists and others involved in the care of cardiology patients, including coverage from major conferences and updates and revisions to major clinical guidelines.
Advertisement
Related to this article
AASM urges CMS to reject proposed 2027 Medicare conversion factor cuts of 1.19% to 1.68% and revise sleep testing and remote monitoring policies.
A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
A higher ratio of red blood cell distribution width to albumin was tied to greater all-cause, cardiovascular, and cancer mortality in adults with CKD.
A meta-analysis of 22 studies found steatotic liver disease in about three-quarters of patients with sleep-disordered breathing.
FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs
Sustainable models require asking what a result shows, what design produced it, and whether the design was built to measure value or just produce a number.
CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.
Advertisement
Advertisement
Trending on AJMC
1
Dual Agonist Survodutide Delivers Up to 13.1% Weight Loss in T2D
2
Retatrutide Yields Up to 20.8% Weight Loss in Obesity With T2D
3
CMS Projects 16.5% Drop in 2027 Medicare Advantage Premiums
4
FDA Accepts Inhaled Treprostinil sNDA for IPF: 4 FAQs for Payers
5